Effects of the dual PPAR-[alpha]/[gamma] agonist aleglitazar on glycaemic control and organ protection in the Zucker diabetic fatty rat

Aims To evaluate the effects of aleglitazar, a dual peroxisome proliferator-activated receptor-[alpha]/[gamma] agonist, on the development of diabetes-related organ dysfunction, in relation to glycaemic and lipid changes, in Zucker diabetic fatty (ZDF) rats. Methods Six-week-old, male ZDF rats recei...

Full description

Saved in:
Bibliographic Details
Published in:Diabetes, obesity & metabolism obesity & metabolism, 2013-02, Vol.15 (2), p.164
Main Authors: Bénardeau, A, Verry, P, Atzpodien, E.-A, Funk, J. M, Meyer, M, Mizrahi, J, Winter, M, Wright, M. B, Uhles, S, Sebokova, E
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Aims To evaluate the effects of aleglitazar, a dual peroxisome proliferator-activated receptor-[alpha]/[gamma] agonist, on the development of diabetes-related organ dysfunction, in relation to glycaemic and lipid changes, in Zucker diabetic fatty (ZDF) rats. Methods Six-week-old, male ZDF rats received aleglitazar 0.3mg/kg/day or vehicle as food admix for 13weeks (n=10 per group). Age-matched male Zucker lean rats served as non-diabetic controls. Plasma and renal markers were measured at several time points. Histopathology and quantitative immunohistochemistry were performed at 13weeks. Results Glycated haemoglobin (5.4 vs. 9.2%) and blood glucose (8.3±0.3 vs. 26.1±1.0mmol/l) were significantly reduced at 12weeks with aleglitazar versus vehicle-treated ZDF rats (both p
ISSN:1462-8902
1463-1326
DOI:10.1111/dom.12006